Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

News Daily News EuroPCR 2025

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Michael O'Riordan

May 28, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation NY Valves 2024

Global Experience With Transapical TMVR - Does Access Impact Clinical Outcomes?

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

TAVR Will Have a Longer Lasting Durability Than SAVR

Presenter: Michael J. Reardon

June 06, 2024

Presentation NY Valves 2024

The Lifetime Management of Aortic Stenosis: A Heart Team Perspective

Presenter: Michael J. Reardon

June 05, 2024

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Shelley Wood

November 27, 2023

Presentation TCT 2023

Current Knowledge of Durability of Bioprosthetic Valves (SAVR and TAVR)

Presenter: Michael Reardon

October 25, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

Presentation TCT 2023

China Experiences with J-Valve TAVR for Both Aortic Regurgitation and Stenosis

Presenter: Michael Reardon

October 23, 2023

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

Advertisement

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Underexpanded Acurate neo2 Valves Tied to Worse Outcomes: ACURATE IDE

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Global Experience With Transapical TMVR - Does Access Impact Clinical Outcomes?

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

TAVR Will Have a Longer Lasting Durability Than SAVR

The Lifetime Management of Aortic Stenosis: A Heart Team Perspective

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Current Knowledge of Durability of Bioprosthetic Valves (SAVR and TAVR)

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Four-Year Outcomes From the EVOLUT Low Risk Trial

China Experiences with J-Valve TAVR for Both Aortic Regurgitation and Stenosis

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content